Navigation Links
Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
Date:11/2/2007

Conference Call Scheduled for 4:30 PM EST - November 7, 2007

WALTHAM, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) today announced that it will release its third quarter financial results on Wednesday, November 7 after the market closes. The Company's management will host the conference call at 4:30 PM EST to review Interleukin's 2007 third quarter financial results and provide management updates.

Conference Call Details

To access the live call on November 7, 2007 at 4:30 PM EST, dial (800) 366-3964 (domestic) or (303) 205-0055 (international). The call will also be available live via webcast at http://www.ilgenetics.com.

Replay access of the teleconference will be available for two weeks following the call by calling (800) 405-2236 (domestic) or (303) 590-3000 (international). The passcode for the replay is 11101550. The webcast will be archived following the call at http://www.ilgenetics.com.

About Interleukin

Interleukin Genetics, Inc. (Amex: ILI - News) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Forward Looking Statements

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, our ability to make progress in advancing our core technologies, and our expectations regarding fiscal year 2007 revenues and gross profit margins of our nutritional supplement products. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Diptheria Toxin And Interleukin2 Help Killing Melanoma Tumour Cells
2. Genetics and cholesterol levels
3. Genetics helps in attacking cancer
4. Alcoholism Influenced By Both Genetics & Family Environment
5. Genetics linked to leukemia treatment success rate in children
6. Genetics Has A Major Role To Play In Body Shape.
7. Revolution in Genetics to Open Avenues for Treating Cancer
8. AIDS research and genetics...
9. Faster way of producing Bird flu vaccine using Reverse Genetics
10. Genetics of Ageing with Preserved Mental Capacity.
11. Generation Scotland To Examine Relation Between Lifestyle, Genetics and Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... quickly sideline athletes. A type of groin injury, it occurs when the muscles ... serious, intense pain in and around the lower torso, as well as accompanying ...
(Date:3/27/2017)... ... 2017 , ... Advantexe Learning Solutions , a global ... new research study, The Business Readiness Report. The report explores the correlation between ... actual success of achieving individual and company goals. , There are many ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... that for a second year in a row; they are the recipient of ... in the industry voted on the award at Design Connections 2017. Top A&D ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
(Date:3/27/2017)... ... 2017 , ... The Anaheim Hills office accelerates and supports FNCC’s growth and ... new sales professionals over the past 6 months and is continuing to recruit new ... the course of 2017. , “This new office is a direct result of ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... N.J. , March 27, 2017 Invivotek, ... and leading in vivo pharmacology contract research ... Farm adjacent to its newly expanded preclinical research facility ... solar farm provides a cleaner, renewable energy source to ... the environment. Completion of the Genesis Solar Farm follows ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal Aortic ... reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 to ... and is projected to dominate the market during the study period. ... ... ...
(Date:3/24/2017)... 24, 2017 New England Pediatric Device Consortium ... award including funding and in-kind service towards the commercialization ... "Making blood draws less traumatic for children ... hospital experience better.  We,re looking forward to working with ... improve care for the kids we treat," said ...
Breaking Medicine Technology: